Abuse-Deterrent Testimony: Hamburg Defends Opioid Policy On The Hill
This article was originally published in The Pink Sheet Daily
Executive Summary
“It doesn’t do any good to label something as abuse-deterrent if it actually isn’t,” the FDA Commissioner tells senators. “And right now, unfortunately, the technology is poor.”
You may also be interested in...
Campaign Against Woodcock’s US FDA Commissioner Bid Has Begun
Opioid issues delayed Robert Califf’s confirmation as FDA commissioner. Could they prevent the nomination of Janet Woodcock?
US FDA Hopes Food, Inspection Office Reorg Bolsters Innovative Clinical Trial Adoption
Ensuring inspectors understand the innovative trial designs in use before an inspection will be important to increasing industry confidence in their use, CDER Director Patrizia Cavazzoni said.
US FDA's CDER Creates Quantitative Medicine Center Of Excellence; Job Includes AI Oversight
The group will coordinate quantitative medicine issues throughout the FDA's Center for Drug Evaluation and Research to help streamline drug development.